24/06/2021 Eli Lilly receives US FDA Breakthrough Therapy designation for donanemab in AD Science watch
23/06/2021 Eisai and Biogen have been granted US FDA Grants Breakthrough Therapy designation for lecanemab in AD Science watch
21/06/2021 Results from the DIAN-TU trial show that gantenerumab reduces key biomarkers in inherited form of Alzheimer’s disease Science watch
16/06/2021 The TANGO Phase II study evaluating gosuranemab in AD did not meet its primary efficacy endpoint Science watch
15/06/2021 European Alzheimer’s Disease Consortium (EADC) responds to FDA approval of aducanumab Science watch
14/06/2021 Results of Phase II ADAMANT trial of AADVac1 for mild Alzheimer's disease published in Nature Aging Science watch
08/06/2021 Anavex completes enrolment of its Phase II/III clinical trial in people with Alzheimer’s disease Science watch
07/06/2021 FDA approves aducanumab, a first disease-modifying treatment for Alzheimer's disease Science watch
01/06/2021 Researchers identify changes in novel plasma proteins that may signal increased dementia risk many years before disease onset Science watch
19/05/2021 Grifols and Fundació Acé announce the launch of an AMBAR Center in Barcelona Science watch
